小児期心疾患に対する抗血小板薬 ticlopidine の有用性と安全性についての検討
|
|
- Candice Ellis
- 5 years ago
- Views:
Transcription
1 原 著 PEDIATRIC CARDIOLOGY and CARDIAC SURGERY VOL.26 NO.5 ( ) 小児期心疾患に対する抗血小板薬 ticlopidine の有用性と安全性についての検討 Key words: ticlopidine, antithrombotic therapy, antiplatelet drug, Fontan procedure, systemic to pulmonary artery shunt Safety and Efficacy of Ticlopidine in Pediatric Patients with Heart Disease Kiyoshi Ogawa, Masatoshi Iijima, Reiji Ito, Sadataka Kawachi, Kenji Sugamoto, Takashi Hishitani, and Kenji Hoshino Division of Pediatric Cardiology, Saitama Children s Medical Center, Saitama, Japan Background: Although prolonged antiplatelet therapy with aspirin is widely recommended for children with heart disease, aspirin alone may not be sufficient to prevent thrombotic events. The safety and efficacy of thienopyridine derivatives such as ticlopidine and clopidogrel have been established in adult patients with coronary artery disease. However, very limited information has been published on the use of ticlopidine in a pediatric population. Methods: A retrospective study of all children treated with ticlopidine was performed. 87 patients with congenital or acquired heart disease were identified. Those patients were divided into three different groups by age and procedures at ticlopidine use. Results: The total daily dose of ticlopidine ranged from 1.0 to 7.4 mg/kg/day. The relationship between the degree of ADPinduced platelet aggregation inhibition and the dose of ticlopidine was not linear in any of the three groups. Two patients developed thrombotic events after systemic to pulmonary artery shunting. There were no serious bleeding events or adverse gastrointestinal effects attributed to the ticlopidine. Hematological abnormalities were documented in 7 patients. Isolated thrombocytopenia was identified in 6 patients 2 to 13 years after the initiation of ticlopidine. Platelet counts gradually decreased in all patients. Conclusions: Ticlopidine was well tolerated in our pediatric patients with heart disease, and adverse events were minimal. The doses of ticlopidine were considerably lower than those for adult use. Patients should be monitored for thrombocytopenia during ticlopidine administration. 要旨 aspirin aspirin clopidogrel ticlopidine ticlopidine 87 3 ADP mg/kg/day 2 6 Ticlopidine
2 401 Table 1 Clinical characteristics Infant Young child Child Total Number Age 14 day 2 y 2 y 7 y 7 y 15 y 14 day 15 y Male/female 18/12 20/11 16/10 54/33 Heart disease SP shunt SP shunt-fontan Fontan Coronary lesion SP shunt: systemic to pulmonary artery shunt 背景 Fontan 1 5 clopidogrel Plavix 6 clopidogrel Ticlopidine Panaldine clopidogrel adenosine diphosphate ADP P2Y12 7 ticlopidine TTP 8 9 clopidogrel Clopidogrel 1 6 mg/kg/day mg/kg/ day ticlopidine 13 Ticlopidine 500 mg/ 3 4 ticlopidine 方法 Fontan ticlopidine Fontan Glenn 3 Fontan Table1 ADP Ticlopidine ticlopidine 2 4 Ticlopidine 5 mg/kg/ 3 ADP PICOLO trial 結果 Ticlopidine ADP Fig mg/kg/day Fig. 2 Fontan Fig. 3 Ticlopidine Fig. 4 ADP
3 402 Fig. 1 Effect of ticlopidine on ADP-induced platelet aggregation. No linear relationship between the degree of ADPinduced platelet aggregation inhibition and the dosage of ticlopidine was detected in pediatric patients with heart disease. Fig. 2 Effect of ticlopidine on ADP-induced platelet aggregation in three different age groups. No linear relationship between the degree of ADP-induced platelet aggregation inhibition and the dosage of ticlopidine was detected in three different age groups. Fig. 3 Effect of ticlopidine on ADP-induced platelet aggregation in children with two different procedure groups. No linear relationship between the degree of ADP-induced platelet aggregation inhibition and the dosage of ticlopidine was detected in children with two different procedure groups
4 403 Fig. 4 Effect of ticlopidine on ADP-induced platelet aggregation in three different age groups. Fig. 5 Time course of ticlopidine dose and % inhibition of platelet aggregation in a child. 1 ticlopidine ADP Fig. 5 Ticlopidine 5 mg/kg 19 Ticlopidine Ticlopidine 1 aspirin 1 γgtp 3 15 /μl
5 404 Fig. 6 Time course of platelet count in cases with thrombocytepenia. The numbers of platelet decreased slowly in all patients and became lower than /mm 3 in 2 patients. Table 2 Clinical characteristics of patients with abnormal platelet count Age at No. Heart disease Operation ticlopidine initiation Ticlopidine dose (mg/kg) # Duration of ticlopidine Hb (g/dl) ## Complication treatment 1 TA, PA Fontan procedure 2m y 15.8 thrombocytopenia 2 PA, VSD, hypo PA pali. RV-PA cond. 1m 4.3 5y2m 12.6 thrombocytopenia 3 SRV Fontan procedure 8y4m 3.1 2y 14.1 thrombocytopenia 4 TGA(III), s-mv Fontan procedure 1m y7m 14.6 thrombocytopenia 5 DORV, hypo LV, PS Fontan procedure 11y2m 2.3 4y6m 16.8 thrombocytopenia 6 HLHS Fontan procedure 1m 2 9y11m 16.0 thrombocytopenia 7 C-TGA, PA, VSD Fontan procedure 2m 3 7y10m 13.6 thrombocytosis # Ticlopidine dose at onset of abnormal platelet count, ## Hemoglobin at onset of abnormal platelet count TA: tricuspid atresia, PA: pulmonary atresia, VSD: ventricular septal defect, hypo PA: hypoplastic pulmonary artery. SRV: single right ventricle, TGA: transposition of the great arteries, s-mv: straddling mitral valve, DORV: double outlet right ventricle, hypo LV: hypoplastic left ventricle, PS: pulmonary stenosis, HLHS: hypoplastic left heart syndrome, C-TGA: corrected trasposition of the great arteries, pali. RV-PA cond.: palliative right ventricle-pulmonary artery couduit 6 40 /μl 1 7 Table 2 6 Fontan 1 palliative RV-PA conduit 1 ticlopidine 2 ticlopidine Fig /μl 1 3 platelet associated IgG PA-IgG 5 aspirin /μl aspirin /μl JAK2 V617F 考案
6 405 6 aspirin dipyridamole warfarin heparin aspirin 14 ticlopidine clopidogrel aspirin 1 5 ticlopidine clopidogrel Page 15 ticlopidine TTP 8 9 ticlopidine clopidogrel ticlopidine TTP ticlopidine aspirin 18 warfarin ticlopidine ticlopidine Ticlopidine aspirin 1990 Ticlopidine 5 mg/kg/day mg/kg/day 21 1 mg/kg/day clopidogrel PICOLO trial mg/ mg/kg/ 5 mg/kg/day ADP 1 mg/kg/day ADP clopidogrel 75 mg/day ADP PICOLO trial ticlopidine ADP PICOLO trial aspirin hyporesponder hyper-responder hypo-responder Ticlopidine BT shunt aspirin aspirin ticlopidine 3 ticlopidine 9 ticlopidine Ticlopidine PA-IgG /μl 1 ticlopidine 3 2 predonisolone 6 PA-IgG 2 ticlopidine 1 Fontan
7 406 clopidogrel 25 clopidogrel Clopidgrel to Lower Arterial thrombotic Risk In Neonates and infants Trial, CLARINET 25 clopidogrel 結論 ticlopidine ticlopidine 参考文献 1 Antiplatelet Trialists Collaboration: Collaborative overview of randomized trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: Antithrombotic Trialists Collaboration: Collaborative metaanalysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: Gent M, Blakely JA, Easton JD, et al: The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 1(8649): Hass WK, Easton JD, Adams Jr HP, et al: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without STsegment elevation. N Engl J Med 2001; 345: Monagle P, Chalmers E, Chan A, et al: Antithrombotic therapy in neonates and children. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 887S 968S 7 Hollopeter G, Jantzen HM, Vincent D, et al: Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, et al: Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med 1998; 128: Love BB, Biller J, Gent M: Adverse haematological effects of ticlopidine. Prevention, recognition and management. Drug Safety 1998; 19: Finkelstein Y, Nurmohamed L, Avner M, et al: Clopidogrel use in children. J Pediatr 2005; 147: Soman T, Rafay M, Hune S, et al: The risk and safety of clopidogrel in pediatric arterial ischemic stroke. Stroke 2006; 37: Li JS, Yow E, Berezny KY, et al: Dosing of clopidogrel for platelet inhibition in infants and young children. Primary results of the platelet inhibition in children on clopidogrel (PICOLO) trial. Circulation 2008; 117: O Brien M, Parness IA, Neufeld EJ, et al: Ticlopidine plus aspirin for coronary thrombosis in Kawasaki disease. Pediatrics 2000; 105: e64 14 Steering Committee of the Physicians Health Study Research Group: Final report on the aspirin component of the ongoing physicians health study. N Engl J Med 1989; 321: Page Y, Tardy B, Zeni F, et al: Thrombotic thrombocytopenic purpura related to ticlopidine. Lancet 1991; 337: ACC/AHA Guideline update for the management of patients with unstable angina and non-st-segment elevation myocardial infarction-2002: Summary article. Circulation 2002; 106: No Li JS, Yow E, Berezny KY, et al: Clinical outcomes of palliative surgery including a systemic-to-pulmonary artery shunt in infants with cyanotic congenital heart disease. Does aspirin make a difference? Circulation 2007; 116: Limet R, David JL, Magotteaux P, et al: Prevention of aortacoronary bypass graft occlusion: Beneficial effect of ticlopidine on early and late patency rates of venous coronary bypass grafts: A double-blind study. J Thorac Cardiovasc Surg 1987; 94: pp Serebruany VL, Steinhubl SR, Berger PB, et al: Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45: Ticlopidine ; 69: Ticlopidine ; 6: : Ticlopidine pp27 25 Mertens L, Eyskens B, Boshoff D, et al: Safety and efficacy of clopidogrel in children with heart disease. J Pediatr 2008; 153:
母親が経験した 子どもの病状を理解する困難さ : 先天性心疾患児の母親におけるインフォームド コンセント
原 著 PEDIATRIC CARDIOLOGY and CARDIAC SURGERY VOL. 26 NO. 4 (290 297) 母親が経験した 子どもの病状を理解する困難さ : 先天性心疾患児の母親におけるインフォームド コンセント 1 2 1 1 3 1) 2) 3) Key words: congenital heart disease, mother, support, informed
More informationIntroduction. Study Design. Background. Operative Procedure-I
Risk Factors for Mortality After the Norwood Procedure Using Right Ventricle to Pulmonary Artery Shunt Ann Thorac Surg 2009;87:178 86 86 Addressor: R1 胡祐寧 2009/3/4 AM7:30 SICU 討論室 Introduction Hypoplastic
More informationClopidogrel has been evaluated in clinical trials that included cardiovascular patients
REVIEW ARTICLE Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations Lessons From the CAPRIE and CURE Studies Jack Hirsh, CM, MD, FRCPC, FRACP, FRSC, DSc; Deepak L. Bhatt, MD,
More information小児および若年者の特発性心房粗動, 心房細動の頻度と特徴 臨床群と誘発群の比較検討
原 著 PEDIATRIC CARDIOLOGY and CARDIAC SURGERY VOL. 26 NO. 4 (332 337) 小児および若年者の特発性心房粗動, 心房細動の頻度と特徴 臨床群と誘発群の比較検討 key words: atrial flutter, atrial fibrillation, electrophysiological study, radiofrequency
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationClopidogrel with Aspirin Is the Optimal Antiplatelet Regimen for Intracoronary Stenting
Clopidogrel Aspirin Steinhubl for and Stenting Topol Journal of Thrombosis and Thrombolysis 1999;7:227 231 Kluwer Academic Publishers. Boston. Printed in the Netherlands. Clopidogrel with Aspirin Is the
More informationOUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.
OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To review the use of antiplatelet agents and oral
More informationTo provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
ACETYL SALICYLIC ACID TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationClopidogrel in Infants with Systemic-to-Pulmonary-Artery Shunts
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article in Infants with Systemic-to-Pulmonary-Artery Shunts David L. Wessel, M.D., Felix Berger, M.D., Jennifer S. Li, M.D., M.H.S., Ingo
More informationMitral Valve Disease, When to Intervene
Mitral Valve Disease, When to Intervene Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Current ACC/AHA guideline Stages
More informationWhen is Risky to Apply Oxygen for Congenital Heart Disease 부천세종병원 소아청소년과최은영
When is Risky to Apply Oxygen for Congenital Heart Disease 부천세종병원 소아청소년과최은영 The Korean Society of Cardiology COI Disclosure Eun-Young Choi The author have no financial conflicts of interest to disclose
More informationQUT Digital Repository:
QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.
More information感染性腹部大動脈瘤の診断における PET-CT 検査の有用性について
Online publication December 27, 2011 総 説 第 51 回総会シンポジウム 5 各種脈管画像診断の進歩と将来展望 感染性腹部大動脈瘤の診断における PET-CT 検査の有用性について 1 1 1 1 1 2 1 要旨 : CT 2007 6 2010 5 97 6 PET-CT CT PET-CT 6 4 2 SUVmax 5.0 FDP SUVmax 3.0 2
More information鎖骨下動脈狭窄に対するカテーテル治療中の椎骨動脈血流変化と血管エコーによるモニターの意義
Online publication December 10, 2009 原 著 第 48 回総会 Young Investigator s Award 鎖骨下動脈狭窄に対するカテーテル治療中の椎骨動脈血流変化と血管エコーによるモニターの意義 1 2 2 2 1 1 1 1 2 要旨 : endovascular treatment: EVT EVT 5 EVT 1 to and fro pattern
More informationWhen to implant an ICD in systemic right ventricle?
When to implant an ICD in systemic right ventricle? Département de rythmologie et de stimulation cardiaque Nicolas Combes n.combes@clinique-pasteur.com Pôle de cardiologie pédiatrique et congénitale Risk
More informationSurvival Rates of Children with Congenital Heart Disease continue to improve.
DOROTHY RADFORD Survival Rates of Children with Congenital Heart Disease continue to improve. 1940-20% 1960-40% 1980-70% 2010->90% Percentage of children with CHD reaching age of 18 years 1938 First Patent
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationChildren with Single Ventricle Physiology: The Possibilities
Children with Single Ventricle Physiology: The Possibilities William I. Douglas, M.D. Pediatric Cardiovascular Surgery Children s Memorial Hermann Hospital The University of Texas Health Science Center
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationSurgical Treatment for Double Outlet Right Ventricle. Masakazu Nakao Consultant, Paediatric Cardiothoracic Surgery
for Double Outlet Right Ventricle Masakazu Nakao Consultant, Paediatric Cardiothoracic Surgery 1 History Intraventricular tunnel (Kawashima) First repair of Taussig-Bing anomaly (Kirklin) Taussig-Bing
More informationCMS Limitations Guide - Radiology Services
CMS Limitations Guide - Radiology Services Starting October 1, 2015, CMS will update their existing medical necessity limitations on tests and procedures to correspond to ICD-10 codes. This limitations
More informationAntiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology
Antiplatelet and Anti-Thrombotic Therapy Ivan Anderson, MD RIHVH Cardiology Outline Anti-thrombotic therapy Risk stratification of stroke with atrial fibrillation DVT and PE treatment Pharmacology Anti-platelet
More informationClinicians and Facilities: RESOURCES WHEN CARING FOR WOMEN WITH ADULT CONGENITAL HEART DISEASE OR OTHER FORMS OF CARDIOVASCULAR DISEASE!!
Clinicians and Facilities: RESOURCES WHEN CARING FOR WOMEN WITH ADULT CONGENITAL HEART DISEASE OR OTHER FORMS OF CARDIOVASCULAR DISEASE!! Abha'Khandelwal,'MD,'MS' 'Stanford'University'School'of'Medicine'
More informationIndex. Hematol Oncol Clin N Am 19 (2005) Note: Page numbers of article titles are in boldface type.
Hematol Oncol Clin N Am 19 (2005) 203 208 Index Note: Page numbers of article titles are in boldface type. A Abciximab, as an antiplatelet agent, 93 94 Acute coronary syndromes, use of antiplatelet drugs
More informationAnticoagulants and Head Injuries. Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar
Anticoagulants and Head Injuries Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar Common Anticoagulants and Indications Coumadin (warfarin) indicated for
More informationはじめに 対象と方法 39: , 2017 SAH 183 WFNS
39:107 原 著 39: 107 112, 2017 1 2 1 1 1 1 要旨 SAH 2010 1 2013 12 SAH 253 183 64 70 WFNS I III 72.7 Fisher CT 3 86.3 19.9 16.6 GR MD 73.2 73.1 80 WFNS Key words: subarachnoid hemorrhage, prognosis, rate of
More informationCOAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY
COAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY VALTER CASATI, M.D. DIVISION OF CARDIOVASCULAR ANESTHESIA AND INTENSIVE CARE CLINICA S. GAUDENZIO NOVARA (ITALY) ANTIPLATELET
More informationAspirin to Prevent Heart Attack and Stroke: What s the Right Dose?
The American Journal of Medicine (2006) 119, 198-202 REVIEW Aspirin to Prevent Heart Attack and Stroke: What s the Right Dose? James E. Dalen, MD, MPH Professor Emeritus, University of Arizona, Tucson
More informationEast and Central African Journal of Surgery Volume 12 Number 2 November /December 2007
23 Modified Blalock-Taussig Shunt in Palliative Cardiac Surgery E.V. Ussiri 1, E.T.M. Nyawawa 1, U. Mpoki 2, E.R. Lugazia 2, G.C. Mannam 3, L.R. Sajja 4. S. Sompali 4 1 Specialist Surgeon, Cardiothoracic
More informationHeart Transplantation in Patients with Superior Vena Cava to Pulmonary Artery Anastomosis: A Single-Institution Experience
Korean J Thorac Cardiovasc Surg 2018;51:167-171 ISSN: 2233-601X (Print) ISSN: 2093-6516 (Online) CLINICAL RESEARCH https://doi.org/10.5090/kjtcs.2018.51.3.167 Heart Transplantation in Patients with Superior
More informationAntithrombotic therapy for patients with congenital heart disease. George Giannakoulas, MD, PhD AHEPA University Hospital Thessaloniki
Antithrombotic therapy for patients with congenital heart disease George Giannakoulas, MD, PhD AHEPA University Hospital Thessaloniki Disclosures Educational fees from Astra Zeneca, GSK Research fees from
More informationAntiplatelet agents treatment
Session III Comprehensive management of diabetic patients Antiplatelet agents treatment Chonnam National University Hospital Department of Internal Medicine Dong-Hyeok Cho CONTENTS Introduction Prothrombotic
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More information頸動脈の超音波検査 頸動脈エコーの原理 患者情報の収集 検査時の患者の体位 超音波装置の条件設定 特集 : 脈管疾患診断における非侵襲的画像診断 : 進歩と現状. J Jpn Coll Angiol :
Online publication January 22, 2010 総 説 特集 : 脈管疾患診断における非侵襲的画像診断 : 進歩と現状 頸動脈の超音波検査 要旨 : J Jpn Coll Angiol 2009 49: 453 458 Key words: brain infarction, transient ischemic attack, amaurosis fugax, intima
More informationDental Management Considerations for Patients on Antithrombotic Therapy
Dental Management Considerations for Patients on Antithrombotic Therapy Warfarin and Antiplatelet Joel J. Napeñas DDS FDSRCS(Ed) Program Director General Practice Residency Program Department of Oral Medicine
More informationPrevention of Coronary Stent Thrombosis and Restenosis
Prevention of Coronary Stent Thrombosis and Restenosis Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea 9/12/03 Coronary
More informationOptimal medical therapy in patients with stable CAD
Optimal medical therapy in patients with stable CAD Robert Storey Professor of Cardiology, University of Sheffield and Academic Director and Honorary Consultant Cardiologist, Cardiology and Cardiothoracic
More informationDear Parent/Guardian,
Dear Parent/Guardian, You have indicated on school records that your child has an ongoing health problem that may require medication and/or treatment during the school day with rescue medication. Attached
More informationAdults with Congenital Heart Disease. Michael E. McConnell MD, Wendy Book MD Teresa Lyle RN NNP
Adults with Congenital Heart Disease Michael E. McConnell MD, Wendy Book MD Teresa Lyle RN NNP Outline History of CHD Statistics Specific lesions (TOF, TGA, Single ventricle) Erythrocytosis Pregnancy History
More informationSeptember 26, 2012 Philip Stockwell, MD Lifespan CVI Assistant Professor of Medicine (Clinical)
September 26, 2012 Philip Stockwell, MD Lifespan CVI Assistant Professor of Medicine (Clinical) Advances in cardiac surgery have created a new population of adult patients with repaired congenital heart
More information"Lecture Index. 1) Heart Progenitors. 2) Cardiac Tube Formation. 3) Valvulogenesis and Chamber Formation. 4) Epicardium Development.
"Lecture Index 1) Heart Progenitors. 2) Cardiac Tube Formation. 3) Valvulogenesis and Chamber Formation. 4) Epicardium Development. 5) Septation and Maturation. 6) Changes in Blood Flow during Development.
More informationCongenital Heart Defects
Normal Heart Congenital Heart Defects 1. Patent Ductus Arteriosus The ductus arteriosus connects the main pulmonary artery to the aorta. In utero, it allows the blood leaving the right ventricle to bypass
More informationCardiac Catheterization Cases Primary Cardiac Diagnoses Facility 12 month period from to PRIMARY DIAGNOSES (one per patient)
PRIMARY DIAGNOSES (one per patient) Septal Defects ASD (Atrial Septal Defect) PFO (Patent Foramen Ovale) ASD, Secundum ASD, Sinus venosus ASD, Coronary sinus ASD, Common atrium (single atrium) VSD (Ventricular
More informationCommon Codes for ICD-10
Common Codes for ICD-10 Specialty: Cardiology *Always utilize more specific codes first. ABNORMALITIES OF HEART RHYTHM ICD-9-CM Codes: 427.81, 427.89, 785.0, 785.1, 785.3 R00.0 Tachycardia, unspecified
More informationAdult Congenital Heart Disease: What All Echocardiographers Should Know Sharon L. Roble, MD, FACC Echo Hawaii 2016
1 Adult Congenital Heart Disease: What All Echocardiographers Should Know Sharon L. Roble, MD, FACC Echo Hawaii 2016 DISCLOSURES I have no disclosures relevant to today s talk 2 Why should all echocardiographers
More informationNew Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel)
New Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel) Limitations and Advantages of UFH and LMWH Biological limitations of UFH : 1. immune-mediated
More informationCYANOTIC CONGENITAL HEART DISEASES. PRESENTER: DR. Myra M. Koech Pediatric cardiologist MTRH/MU
CYANOTIC CONGENITAL HEART DISEASES PRESENTER: DR. Myra M. Koech Pediatric cardiologist MTRH/MU DEFINITION Congenital heart diseases are defined as structural and functional problems of the heart that are
More informationDECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
More informationIn 1980, Bex and associates 1 first introduced the initial
Technique of Aortic Translocation for the Management of Transposition of the Great Arteries with a Ventricular Septal Defect and Pulmonary Stenosis Victor O. Morell, MD, and Peter D. Wearden, MD, PhD In
More informationCardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008.
Cardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008. ST Elevation Myocardial Infarction (STEMI)-Acute Coronary Syndrome Guidelines:
More informationCardiac CT in Infants with Congenital heart disease Sunrise Session. LaDonna Malone, MD May 17, 2018
Cardiac CT in Infants with Congenital heart disease Sunrise Session LaDonna Malone, MD May 17, 2018 None Disclosures Objectives Describe cardiac CT techniques used in infants with congenital heart disease.
More information가천의대길병원소아심장과최덕영 PA C IVS THE EVALUATION AND PRINCIPLES OF TREATMENT STRATEGY
가천의대길병원소아심장과최덕영 PA C IVS THE EVALUATION AND PRINCIPLES OF TREATMENT STRATEGY PA c IVS (not only pulmonary valve disease) Edwards JE. Pathologic Alteration of the right heart. In: Konstam MA, Isner M, eds.
More informationThe modified natural history of congenital heart disease
The modified natural history of congenital heart disease Matthias Greutmann, MD Adult Congenital Heart Disease Program University Hospital Zurich, Switzerland matthias.greutmann@usz.ch Are we ready for
More informationDownloaded from:
Antithrombotic Trialists Collaboration. (inc. Meade, TW), (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high
More information3/14/2011 MANAGEMENT OF NEWBORNS CARDIAC INTENSIVE CARE CONFERENCE FOR HEALTH PROFESSIONALS IRVINE, CA. MARCH 7, 2011 WITH HEART DEFECTS
CONFERENCE FOR HEALTH PROFESSIONALS IRVINE, CA. MARCH 7, 2011 MANAGEMENT OF NEWBORNS WITH HEART DEFECTS A NTHONY C. CHANG, MD, MBA, MPH M E D I C AL D I RE C T OR, HEART I N S T I T U T E C H I LDRE N
More information325 mg aspirin and plavix
325 mg aspirin and plavix 12-3-2006 Background Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for. Compare Aspirin
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationArteriopatie periferiche. Trattamento delle arteriopatie periferiche: AVK versus Antiaggregante
Arteriopatie periferiche Trattamento delle arteriopatie periferiche: AVK versus Antiaggregante Anna Falanga USC Immunoematologia e Medicina Trasfusionale ASST Papa Giovanni XXIII, Bergamo Obiettivi della
More informationGuidelines for Anticoagulation in Paediatric Cardiac Patients
Leeds Children s Hospital Guidelines for Anticoagulation in Paediatric Cardiac Patients SURGICAL PATIENTS Preoperative Management Blalock-Taussig (BT) Shunt / Fontan circulation / Sano Shunt and Severe
More informationCardiovascular Pathophysiology: Right to Left Shunts aka Cyanotic Lesions
Cardiovascular Pathophysiology: Right to Left Shunts aka Cyanotic Lesions Ismee A. Williams, MD, MS iib6@columbia.edu Pediatric Cardiology Learning Objectives To discuss the hemodynamic significance of
More informationCardiovascular Pathophysiology: Right to Left Shunts aka Cyanotic Lesions Ismee A. Williams, MD, MS Pediatric Cardiology
Cardiovascular Pathophysiology: Right to Left Shunts aka Cyanotic Lesions Ismee A. Williams, MD, MS iib6@columbia.edu Pediatric Cardiology Learning Objectives To discuss the hemodynamic significance of
More informationOral Antiplatelet Therapy in PCI/ACS. Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine
Oral Antiplatelet Therapy in PCI/ACS Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine Basic Concepts Thrombus Formation Two key elements:
More informationPrasugrel: Son of Clopidogrel or Distant Cousin? Disclosures. Objectives
Prasugrel: Son of Clopidogrel or Distant Cousin? By John J. Bon, Pharm.D., BCPS Lead Clinical Pharmacist, Critical Care Summa Health System Disclosures I have no actual or potential conflict of interest
More informationCongenital Heart Disease
Congenital Heart Disease Mohammed Alghamdi, MD, FRCPC, FAAP, FACC Associate Professor and Consultant Pediatric Cardiology, Cardiac Science King Fahad Cardiac Centre King Saud University INTRODUCTION CHD
More informationHow Long Patietns Will Be on Dual Antiplatelet Therapy?
How Long Patietns Will Be on Dual Antiplatelet Therapy? Ron Waksman,, MD, FACC Professor of Medicine (Cardiology) Georgetown University Associate Director, Division of Cardiology, Washington Hospital Center
More informationSimple, Rapid Antiplatelet Therapy Response Assessment
Simple, Rapid Antiplatelet Therapy Response Assessment Acute Care Diagnostics Antiplatelet therapy. Is it working? At least 1 in 3 patients on antiplatelet therapies do not receive the intended physiological
More informationGlenn Shunts Revisited
Glenn Shunts Revisited What is a Super Glenn Patricia O Brien, MSN, CPNP-AC Nurse Practitioner, Pediatric Cardiology No Disclosures Single Ventricle Anatomy Glenn Shunt Cavopulmonary Anastomosis Anastomosis
More informationM/3, cc-tga, PS, BCPC(+) Double Switch Operation
2005 < Pros & Cons > M/3, cc-tga, PS, BCPC(+) Double Switch Operation Congenitally corrected TGA Atrio-Ventricular & Ventriculo-Arterial discordance Physiologically corrected circulation with the morphologic
More informationLow-dose aspirin increases aspirin resistance in patients with coronary artery disease
The American Journal of Medicine (2005) 118, 723-727 CLINICAL RESEARCH STUDY AJM Theme Issue: CARDIOLOGY Low-dose aspirin increases aspirin resistance in patients with coronary artery disease Pui-Yin Lee,
More informationLOW DOSE ASPIRIN CARDIOVASCULAR DISEASE FOR PROPHYLAXIS OF FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING
LOW DOSE ASPIRIN FOR PROPHYLAXIS OF CARDIOVASCULAR DISEASE FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING Use of Low Dose Aspirin to Treat and Prevent Cardiovascular Disease In recent decades, aspirin
More informationFastTest. You ve read the book now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More informationPreoperative Echocardiographic Assessment of Uni-ventricular Repair
Preoperative Echocardiographic Assessment of Uni-ventricular Repair Salem Deraz, MD Pediatric Cardiologist, Aswan Heart Centre Magdi Yacoub Heart Foundation Uni-ventricular repair A single or series of
More informationAnti-platelet therapies and dual inhibition in practice
Anti-platelet therapies and dual inhibition in practice Therapeutics; Sept. 25 th 2007 Craig Williams, Pharm.D. Associate Professor of Pharmacy Objectives 1. Understand the pharmacology of thienopyridine
More informationCavitary Pulmonary Nontuberculous Mycobacterium Infection in an Adult Patient with Cyanotic Congenital Heart Disease
PEDIATRIC CARDIOLOGY and CARDIAC SURGERY VOL. 25 NO. 1 (56 60) 1 1 1 2 2 3 4 1 2 3 4 Cavitary Pulmonary Nontuberculous Mycobacterium Infection in an Adult Patient with Cyanotic Congenital Heart Disease
More informationPreoperative Management of Patients Receiving Antithrombotics
Preoperative Management of Patients Receiving Antithrombotics Bleeding complications remain an important concern for most surgical procedures. Attempts to minimize the risk of these complications by removing
More informationCardiac Emergencies in Infants. Michael Luceri, DO
Cardiac Emergencies in Infants Michael Luceri, DO October 7, 2017 I have no financial obligations or conflicts of interest to disclose. Objectives Understand the scope of congenital heart disease Recognize
More informationStephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More informationAdult with Cyanotic Congenital Heat Disease
Adult with Cyanotic Congenital Heat Disease Savitri Srivastava Director, Pediatric & Congenital Heart Disease Fortis Escorts Heart Institute Okhla Road, New Delhi Cyanotic Adult WCC & IVUS 2015 Adult Cyanotic
More informationThe complications of cardiac surgery:
The complications of cardiac surgery: a walk on the Dark Side? Prof Rik De Decker Red Cross Children s Hospital CME Nov/Dec 2011 http://www.cmej.org.za Why should you care? You are about to leave your
More informationLow Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)
Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Caitlin C. Akerman, PharmD PGY2 Cardiology Resident WakeMed Health & Hospitals Raleigh,
More informationCase Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA
Case Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA Case History A 50-year-old man with type 1 diabetes mellitus and hypertension presents after experiencing 1 hour of midsternal chest pain that began after
More informationHorizon Scanning Centre November 2012
Horizon Scanning Centre November 2012 Cangrelor to reduce platelet aggregation and thrombosis in patients undergoing percutaneous coronary intervention99 SUMMARY NIHR HSC ID: 2424 This briefing is based
More informationIndex. radiologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A ALCAPA. See Anomalous left coronary artery from the pulmonary artery. Angiosarcoma computed tomographic assessment of, 809 811 Anomalous
More information( Aspirin ) ( Stroke ) ( Dosage ) ( Diabetes ) ( Metabolic syndrome ) ( Primary prevention ) Aspirin Aspirin Aspirin. Aspirin.
2007 18 1-10 ( 75 150 mg/day ) ( American Heart Association AHA ) ( American Diabetes Association ADA ) 75 150 mg/day ( ) ( ) ( Stroke ) ( Dosage ) ( Diabetes ) ( Metabolic syndrome ) ( Primary prevention
More information5.8 Congenital Heart Disease
5.8 Congenital Heart Disease Congenital heart diseases (CHD) refer to structural or functional heart diseases, which are present at birth. Some of these lesions may be discovered later. prevalence of Chd
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More information- May Help Increase Appropriate Early Use in Acute Coronary Syndrome Patients -
MEDIA INVESTORS Ken Dominski John Elicker Bristol-Myers Squibb Bristol-Myers Squibb 609-252-5251 212-546-3775 ken.dominski@bms.com john.elicker@bms.com Amy Ba Felix Lauscher sanofi-aventis sanofi-aventis
More informationCytochrome P450 interactions
Cytochrome P450 interactions Learning objectives After completing this activity, pharmacists should be able to: Explain the mechanism of action of clopidogrel-ppi interaction Assess the risks and benefits
More informationTRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006
TRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006 CTU blood product transfusion guidelines 2006 1 Summary of guidelines RED CELLS (10-15ml/kg) This applies to ward patients / icu patients who are stable.
More informationTGA, VSD, and LVOTO. Cheul Lee, MD. Department of Thoracic and Cardiovascular Surgery Sejong General Hospital
Surgical Management of TGA, VSD, and LVOTO Cheul Lee, MD Department of Thoracic and Cardiovascular Surgery Sejong General Hospital TGA, VSD, and LVOTO Incidence : 0.7% of all CHD 20% of TGA with VSD 4%
More informationFoetal Cardiology: How to predict perinatal problems. Prof. I.Witters Prof.M.Gewillig UZ Leuven
Foetal Cardiology: How to predict perinatal problems Prof. I.Witters Prof.M.Gewillig UZ Leuven Cardiopathies Incidence : 8-12 / 1000 births ( 1% ) Most frequent - Ventricle Septum Defect 20% - Atrium Septum
More informationHEART OF THE MATTER: cardiac issues in safe endoscopy & sedation
HEART OF THE MATTER: cardiac issues in safe endoscopy & sedation YUVAL KONSTANTINO M.D. CARDIOLOGY DEPARTMENT, ELECTROPHYSIOLOGY UNIT, SOROKA MEDICAL CENTER, BEN-GURION UNIVERSITY OUTLINE 1 2 3 Anticoagulation
More informationAspirin Dose for Cardiovascular Indications
PL Detail-Document #280901 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER September 2012 Aspirin Dose
More informationXarelto (rivaroxaban)
Xarelto (rivaroxaban) Policy Number: 5.01.575 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Xarelto
More informationHeart disease is the leading cause of death
ACS AND ANTIPLATELET MANAGEMENT: UPDATED GUIDELINES AND CURRENT TRIALS Christopher P. Cannon, MD,* ABSTRACT Acute coronary syndrome (ACS) is an important cause of morbidity and mortality in the US population
More informationYes No Unknown. Major Infection Information
Rehospitalization Intervention Check any that occurred during this hospitalization. Pacemaker without ICD ICD Atrial arrhythmia ablation Ventricular arrhythmia ablation Cardioversion CABG (coronary artery
More informationDr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre
Dr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre Objectives To learn what s new in stroke care 2010-11 1) Acute stroke management Carotid artery stenting versus surgery for symptomatic
More information